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STAT3 
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Highlights 
• Deregulated gp130 activation in gp130F/F:ApoE-/- mice suppresses atherosclerosis. 
• Modulation of aortic plaque formation by gp130 is independent of STAT3 signalling.  
• Gp130/STAT3 signalling promotes plaque macrophage infiltrates and SAA production. 
• Gp130 signalling in bone marrow cells does not contribute to atherosclerosis. 
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Abstract  
Objective: Interleukin (IL)-6 is a key modulator of the acute phase response (APR), and while both 
are implicated in atherosclerosis, the pathological role of specific IL-6 signalling cascades is ill-
defined. Since IL-6 employs the cytokine receptor gp130 to primarily activate the STAT3 pathway, 
here we evaluate whether gp130-dependent STAT3 activation modulates atherosclerosis. 
Methods: High-fat diet-induced atherosclerosis was established in ApoE-/- mice crossed with 
gp130F/F knock-in mice displaying elevated gp130-dependent STAT3 activation and production of 
the APR protein, serum amyloid A (SAA). Also generated were gp130F/F:Stat3-/+:ApoE-/- mice 
displaying genetically-normalised STAT3 activation and SAA levels, and bone marrow chimeras 
involving ApoE-/- and gp130F/F:ApoE-/- mice. At 10 weeks post high-fat diet, aortic atherosclerotic 
lesions, including the presence of CD68+ macrophages, and plasma lipid and SAA profiles, were 
assessed.  
Results: Aortic plaque development and plasma triglyceride levels in gp130F/F:ApoE-/- mice were 
significantly reduced (3-fold, P<0.001) compared to ApoE-/- littermates. By contrast, in 
gp130F/F:ApoE-/- mice, atherosclerotic plaques contained augmented CD68+ macrophage infiltrates, 
and plasma SAA levels were elevated, compared to ApoE-/- mice. Atherosclerotic lesion 
development and plasma triglyceride levels in gp130F/F:ApoE-/- and gp130F/F:Stat3-/+:ApoE-/- mice 
were comparable, despite a significant (P<0.05) reduction in macrophage numbers in lesions, and 
also plasma SAA levels, in gp130F/F:Stat3-/+:ApoE-/- mice. Aortic plaque development and plasma 
triglyceride levels were comparable in ApoE-/- mice reconstituted with gp130F/F:ApoE-/- 
(ApoEF/F:ApoE) or ApoE-/- (ApoEApoE) bone marrow cells.  
Conclusions: Deregulation of gp130/STAT3 signalling augments the APR and macrophage 
infiltration during atherosclerosis without impacting on the development of aortic plaques.  
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1. Introduction 
Atherosclerosis is the predominant underlying pathology of cardiovascular disease, and its 
prevalence world-wide has reached epidemic proportions due to the adoption of a Western life-style 
comprising a diet high in cholesterol and saturated fats.1 In addition to clinical studies, mouse 
disease models have been extensively used to gain insights into the cellular and molecular 
pathogenesis of atherosclerosis, with mice deficient in ApoE (ApoE-/-), a key apolipoprotein 
involved in the regulation of lipoprotein metabolism, being the most widely-investigated model due 
to their hyper-susceptibility to atherosclerosis when fed a high-fat, Western-style diet.2 Collectively, 
these studies have revealed that immune deregulation, leading to chronic inflammation in the 
arterial wall, as well as lipid metabolism affecting circulating cholesterol and triglyceride levels, 
play a causal role in promoting atherosclerosis.3-6 
Interleukin-6 (IL-6) is a potent immunomodulatory cytokine with pro- and anti-inflammatory 
properties involved in the regulation of the acute phase response (APR), as well as modulation of 
lipid homeostasis and vascular remodelling.7,8 These complex and pleiotropic actions of IL-6 within 
the cardiovascular system most likely explain, at least in part, the contradictory roles that have been 
attributed to IL-6 in the development of atherosclerosis in several mouse models. For instance, 
exogenous addition of IL-6 to ApoE-/- mice potentiates disease severity,9 and genetically modified 
ApoE-/- mice unable to elicit the hepatic-driven APR via IL-6 are protected against atherosclerosis,10 
indicating a pro-atherogenic role for IL-6 and the APR. Conversely, IL-6 deficiency in the 
susceptible LDL receptor knock-out (Ldlr-/-) mice impaired the production of the key APR protein 
serum amyloid A (SAA) but had no effect on the development of atherosclerosis,11 and others have 
suggested an anti-atherogenic role for IL-6 based on the augmented development of atherosclerotic 
lesions in either ApoE-/- or ApoE-/+ mice deficient in IL-6.12,13 While these observations imply that 
IL-6 and its downstream signalling pathways are crucial determinants in disease pathogenesis, the 
identity of gp130 signalling pathways which promote these diverse and contrasting atherogenic 
actions for IL-6 remains ill-defined. 
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IL-6 signals via the common signal-transducing receptor subunit gp130, which it shares with 
several related cytokines including IL-11, IL-27, oncostatin M, ciliary neurotrophic factor, and 
leukemia inhibitory factor among others.14 Ligand-induced dimerization of gp130 leads to 
activation of gp130-associated Janus kinases (JAKs), which tyrosine phosphorylate (pY) gp130 to 
primarily facilitate the recruitment of signal transducer and activator of transcription (STAT) 3, and 
to a lesser extent STAT1 and the SH2-containing tyrosine phosphatase 2 (SHP2), the latter of which 
mediates activation of extracellular-regulated kinase (ERK) mitogen-activated protein kinase 
(MAPK) and phosphoinositide-3-kinase (PI3K)/Akt signalling pathways.14 In addition, the pY757 
amino acid of murine gp130 protein (pY759 of human gp130) plays a crucial role in attenuation of 
gp130/STAT3 signalling by recruiting suppressor of cytokine signalling (SOCS)3 to gp130, which 
leads to proteosomal degradation of the receptor signalling complex.15 
Several in vivo approaches designed to artificially modulate STAT3 activity, either indirectly 
by targeting SOCS3 or more directly by modulating STAT3 expression levels, have not only led to 
conflicting observations regarding the role of STAT3 during atherogenesis, but also have not 
addressed which upstream cytokine receptor system is responsible for activation of STAT3.16-19 In 
this current study, we have used gp130F/F knock-in mice displaying endogenous gp130-dependent 
STAT3 hyper-activation20,21 on the ApoE-/- background to elucidate the role of this signalling axis in 
atherosclerosis. Here, we report that gp130F/F:ApoE-/- mice are largely protected against 
atherosclerosis when fed a high-fat diet, which is concomitant with specific alterations to their lipid 
profile. The development of atherosclerotic lesions was comparable in both gp130F/F and compound 
mutant gp130F/F:Stat3-/+ mice21 on the ApoE-/- background, despite the latter displaying genetically-
normalised endogenous STAT3 signalling, decreased plasma SAA levels, and reduced macrophage 
infiltrates in plaques. Furthermore, bone marrow chimeras revealed that the suppressed 
atherosclerosis was independent of altered gp130 signalling in haemopoietic-derived (i.e. immune) 
cells. Collectively, these data suggest that the suppression of atherosclerosis in gp130F/F:ApoE-/- 
mice is independent of the endogenous gp130/STAT3/SAA axis. 
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2. Materials and methods 
2.1 Mice and experimental induction of atherosclerosis 
The gp130F/F and gp130F/F:Stat3-/+ mice on a mixed 129Sv×C57BL/6 background20,21 were back-
crossed 10 generations onto a C57BL/6 background prior to mating with C57BL/6 ApoE-/- mice 
(provided by P. Tipping, Monash University, Australia). Male and female mice aged 8 weeks were 
fed an atherogenic high-fat, Western-style diet comprising 0.15% cholesterol and 21% milk fat 
(Specialty Feeds, Glen Forrest, Australia) ad libitum for 10 weeks. All mice were housed under 
specific pathogen-free conditions, and experiments were approved by the Monash Medical Centre 
‘A’ Monash University Animal Ethics Committee. 
 
2.2 Bone marrow reconstitution 
Bone marrow reconstitution experiments were performed as described previously.22 Briefly, 
unfractionated bone marrow cells (5×106) from ApoE-/- and gp130F/F:ApoE-/- mice were injected 
intravenously into lethally γ-irradiated (2×5.5Gy) 8 week old ApoE-/- mice. At 8 weeks post-transfer, 
mice were fed a high-fat diet for 10 weeks. The successful reconstitution of mice was determined 
by measuring spleen weights and circulating blood platelet counts, as described previously.23 
 
2.3 Assessment of atherosclerosis  
Aortas were dissected and perfused to allow for quantification of atherosclerotic lesions in Oil Red 
O-stained aortic root sections as described previously.24 Immunohistochemistry was performed with 
an anti-CD68 antibody (clone FA-11, kindly provided by P. Tipping, Monash University, Australia) 
as described previously.25  
 
2.4 Plasma profiling  
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Blood was collected after overnight fasting, and total plasma cholesterol and triglyceride levels 
were determined.24 SAA protein levels were determined by ELISA (Biosource, Camarillo, 
California, USA) as per the manufacturer’s instructions.  
 
2.5 Statistical analyses 
Statistical analyses were performed using GraphPad Prism for Windows version 5.0. The normality 
of data was assessed using the D'Agostino and Pearson omnibus K2 normality test. Where 
appropriate, parametric (one-way ANOVA, student t-test) or nonparametric tests (Kruskal Wallis, 
Mann-Whitney U test) were used to determine differences between genotypes. A P<0.05 was 
considered statistically significant. Data are expressed as the mean±standard error of the mean 
(SEM). 
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3. Results 
3.1 Amelioration of atherosclerosis in ApoE-deficient mice with altered gp130 signalling  
The gp130F/F:ApoE-/- and ApoE-/- littermate control mice (8 weeks old) were fed a high-fat, Western-
style diet for 10 weeks. Although the gp130F/F:ApoE-/- mice weighed slightly less than their ApoE-/- 
counterparts prior to being fed a high-fat diet, the mean body weight increase of both 
gp130F/F:ApoE-/- or ApoE-/- mice was comparable over the 10 week course of high-fat diet (Fig. 1A). 
Notably, the percentage of the aortic root occupied by plaques (red-stained areas) was significantly 
reduced (~3-fold) in gp130F/F:ApoE-/- compared to ApoE-/- mice (gp130F/F:ApoE-/-, 9.925±1.357% 
versus ApoE-/-, 23.960±1.744 %, P<0.001) (Fig. 1B,C). Similarly, further quantification indicated 
that the total plaque area was significantly smaller in gp130F/F:ApoE-/- versus ApoE-/- mice 
(gp130F/F:ApoE-/-, 0.05906±0.008962mm2 versus ApoE-/-, 0.1733±0.01772 mm2, P<0.001) (Fig. 
1D). The amelioration of atherosclerotic plaque formation in gp130F/F:ApoE-/- mice was specifically 
in response to high-fat diet, since there was no significant plaque formation in either 
gp130F/F:ApoE-/- or ApoE-/- mice fed a normal chow diet for up to 6 months (data not shown). 
While alterations to lipid metabolism can influence the pathogenesis of atherosclerosis,5,26 the 
role of gp130 signalling in modulating systemic lipid levels during atherosclerosis remains 
controversial.12,13,27 Serum lipid profiling of high-fat diet-fed gp130F/F:ApoE-/- and ApoE-/- mice 
revealed a significant reduction in the level of serum triglycerides in gp130F/F:ApoE-/- mice (Fig. 
2A), whereas total, HDL and LDL cholesterol levels were comparable between the two genotypes 
(Fig. 2B-D). To control for any effects of the high-fat diet, similar serum levels of total, HDL and 
LDL cholesterol, and triglycerides, were observed in 9 month old gp130F/F:ApoE-/- and ApoE-/- mice 
fed a normal chow diet (Supplemental Fig. 1). These data therefore indicate that alterations to 
endogenous gp130 signalling specifically influences the systemic production of triglycerides in 
response to high-fat diet, the suppression of which correlated with reduced atherosclerosis in 
gp130F/F:ApoE-/- mice. 
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3.2 Suppressed atherosclerosis in gp130F/F:ApoE-/- mice does not correlate with reduced aortic 
plaque macrophage infiltration or plasma SAA levels 
To examine whether the reduction in aortic plaque development in gp130F/F:ApoE-/- mice correlated 
with suppressed inflammation, we next performed immunohistochemistry with the CD68 antibody 
to detect infiltrating macrophages, which represent the majority of inflammatory cell infiltrates in 
atherosclerotic plaques. However, the extent of macrophages in atherosclerotic lesions in 
gp130F/F:ApoE-/- mice appeared higher than that in lesions from ApoE-/- mice fed a high-fat diet (Fig. 
3A). Further quantification also confirmed that the percentage of CD68+ macrophages in 
atherosclerotic plaques was significantly higher in high-fat diet-fed gp130F/F:ApoE-/- compared to 
ApoE-/- mice (Fig. 3B). Since the gp130-mediated APR, in particular SAA production, has been 
linked to the recruitment of macrophages into aortic plaques,10 we also examined whether the high-
fat diet affected SAA levels in the plasma of gp130F/F:ApoE-/- mice. Indeed, SAA plasma levels 
were significantly increased by ~20-fold in gp130F/F:ApoE-/- mice compared to ApoE-/- mice (Fig. 
3C). Collectively, these observations suggest that the suppressed atherosclerosis in high-fat diet-fed 
gp130F/F:ApoE-/- mice occurs independently of the gp130-mediated APR and macrophage 
infiltration in atherosclerotic plaques. 
 
3.3 Activation of gp130/STAT3 signalling in gp130F/F:ApoE-/- mice influences the APR and aortic 
plaque macrophage infiltration, but not the development of atherosclerosis  
In light of the above observations, together with conflicting data regarding the effect of artificially-
modulating STAT3 activation levels in vivo during atherogenesis,16-19, we genetically defined 
whether modulating (i.e. normalising) endogenous STAT3 activity in gp130F/F:ApoE-/- mice would 
influence high-fat diet-induced atherosclerosis. High-fat diet-fed gp130F/F:Stat3-/+:ApoE-/- and 
gp130F/F:ApoE-/- mice had a comparable serum lipid metabolism profile, with serum levels of 
triglycerides remaining similarly reduced in both genotypes compared to ApoE-/- mice (Fig. 4A-D). 
Moreover, the percentage of the aortic root in gp130F/F:Stat3-/+:ApoE-/- mice occupied by 
atherosclerotic plaques, as well as the total plaque area itself, were comparable to those in 
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gp130F/F:ApoE-/- mice and remained significantly lower than ApoE-/- mice (Fig. 4E-G). In contrast to 
these findings, the staining of CD68+ macrophages in aortic plaques from gp130F/F:Stat3-/+:ApoE-/- 
mice was lower than gp130F/F:ApoE-/- mice (Supplemental Fig. 2A), and comparable to that 
observed in parental ApoE-/- mice (Fig. 3A). In addition, SAA plasma levels were significantly 
reduced in gp130F/F:Stat3-/+:ApoE-/- mice compared to gp130F/F:ApoE-/- mice (Supplemental Fig. 
2B), and were similar to those in ApoE-/- mice (Fig. 3C). These data therefore indicate that 
endogenous gp130/STAT3 signalling modulates the APR and macrophage recruitment processes 
during high-fat diet-induced atherosclerosis, however these gp130/STAT3-driven processes are 
insufficient to influence disease pathogenesis in gp130F/F:ApoE-/- mice. 
 
3.4 Altered gp130 signalling in bone marrow-derived immune cells does not influence 
atherosclerosis in ApoE-deficient mice  
The above data suggest that gp130 signalling in macrophages does not play a critical role in 
influencing atherosclerotic outcomes. We therefore investigated whether aberrant haemopoietic-
specific gp130 signalling in gp130F/F:ApoE-/- mice influenced their atherogenic hyposensitivity to a 
high-fat diet. We generated radiation chimeras, whereby ApoE-/- mice were lethally irradiated and 
reconstituted with either heterologous gp130F/F:ApoE-/- (ApoEF/F:ApoE) or as a control autologous 
ApoE-/- (ApoEApoE) bone-marrow cells. Since gp130F/F mice spontaneously develop bone marrow-
driven splenomegaly and thrombocytosis,28 spleen weights and circulating platelet counts for both 
naïve and reconstituted mice were used as patho-physiological indicators to confirm the successful 
reconstitution of donor bone marrow cells into recipient mice (Supplemental Fig. 3).  
Atherosclerotic plaque formation was comparable between both ApoEF/F:ApoE and ApoEApoE 
groups of chimeric mice fed a high-fat diet (Fig. 5A-C). Importantly, the percentage of the aortic 
root occupied by plaques, as well as the size (area) of the plaques, was similar between ApoEApoE 
(Fig. 5B,C) and their naïve ApoE-/- counterparts (Fig. 1B-D), indicating that the irradiation 
associated with bone marrow transplantation protocol does not affect atherosclerosis. Serum levels 
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of triglycerides in high-fat diet-fed ApoEF/F:ApoE mice also remained significantly higher than those 
in naïve gp130F/F:ApoE-/- mice, and were unchanged compared to naïve ApoE-/- or ApoEApoE mice 
(Fig. 5D). Taken together, these data indicate that alterations to gp130 signals in haemopoietic-
derived immune cells from gp130F/F:ApoE-/- mice do not influence atherosclerosis. 
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4. Discussion 
Over the last two decades experimental and clinical data have collectively implicated either IL-6, its 
signalling receptor gp130, or its primary downstream signal-transducing transcription factor STAT3 
in influencing the pathogenesis of atherosclerosis. Despite these observations, we are not aware of 
any study which has previously addressed the role of specific gp130-dependent signalling pathways 
in disease pathogenesis. Thus, our understanding of the role of the endogenous gp130/STAT3 
signalling cascade in modulating the development of atherosclerosis in vivo remains unclear. Here, 
by genetically altering the level of endogenous STAT3 activity in the gp130F/F mouse model (on the 
ApoE-/- background) displaying gp130/STAT3 hyper-active signalling, we demonstrate that while 
gp130/STAT3 hyper-activation augmented both the accumulation of macrophages in aortic lesions 
and the systemic APR (as measured by increased plasma SAA production) during high-fat diet-
induced atherosclerosis, this alone was not sufficient to promote the development of aortic plaques. 
Indeed, this latter observation is supported by the recent finding that SAA deficiency in ApoE-/- 
mice has no effect on the development of aortic lesions29. Rather, we reveal here that 
gp130F/F:ApoE-/-  mice were protected against the development of atherosclerotic lesions in a 
gp130/STAT3-independent manner, which was associated with a specific decrease in plasma 
triglyceride levels, the latter observation consistent with clinical data suggesting that lower plasma 
triglyceride levels correlate with reduced risk of cardiovascular disease.5 
The role of STAT3 in experimentally-induced atherosclerosis is controversial, and has largely 
relied on methods to either directly modulate the expression levels of total STAT3 or indirectly alter 
the activation status of STAT3, the latter by modulating the expression levels of SOCS3 which 
upon association with specific receptors (such as gp130) suppresses receptor-mediated STAT3 
activation. For instance, an anti-atherogenic role for STAT3 has been suggested from the 
demonstration that adenoviral-mediated gene delivery of wild-type STAT3 to Ldlr-/- mice fed a 
high-fat diet suppressed atherosclerosis with a concomitant reduction in lesion-associated 
macrophage infiltrates.16 In addition, the conditional ablation of Socs3 in T cells augmented STAT3 
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activation which correlated with a reduction in the development of atherosclerotic lesions, albeit 
without any changes in the numbers of infiltrating macrophages.18 Conversely, STAT3 has been 
proposed to promote atherogenesis, as evidenced by the administration of ApoE-/- mice with anti-
sense oligonucleotides against SOCS3 which augmented STAT3 activity and led to increased aortic 
plaque development and macrophage infiltration.17 Furthermore, genetic ablation of Stat3 in the 
endothelial and, to a lesser extent, the hematopoietic compartments ameliorated both the formation 
of atherosclerotic lesions and the associated macrophage content in response to a high-fat diet, 
suggesting that STAT3 activation in multiple cell types can contribute to disease pathogenesis.19 
Indeed, this notion is supported by clinical studies investigating the expression of activated STAT3 
in human atherosclerotic lesions collected by carotid endarterectomy, which indicate that STAT3 is 
activated in a wide variety of cell types within human lesions, including endothelial, inflammatory 
(macrophages, T cells) and vascular smooth muscle cells.18,19 Notably, such clinical data have also 
further highlighted the contrasting atherogenic roles assigned to STAT3, with one study revealing 
that high STAT3 activity (anti-atherogenic) is associated with lesions containing low macrophage 
(i.e. inflammatory cell) numbers,18 while conversely another study indicated a positive correlation 
between high STAT3 activation levels (pro-atherogenic) and lesions with high grade 
inflammation.19  
While the opposing atherogenic roles assigned to STAT3 during the above-mentioned 
experimentally-induced models of atherosclerosis could be explained, at least in part, by 
experimental differences including the mouse strains (ApoE-/-, Ldlr-/-) and diet used, it is important 
to note that the differential production of STAT3-activating cytokines during these experimentally-
induced atherosclerosis models, and for that matter human disease, is likely to influence whether 
STAT3 suppresses or promotes disease pathogenesis. In this regard, the anti-atherogenic role 
proposed for STAT3 has been in the context of facilitating the anti-inflammatory actions of IL-10 
and/or IL-17 which were up-regulated during disease pathogenesis, although a potential direct link 
between IL-10/STAT3 and/or IL-17/STAT3 in these atherosclerosis models was not 
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investigated.16,18 The anti-atherogenic actions of IL-17 were assigned to the dampening of T cell 
infiltration into forming lesions18, which contrasts its reported pro-atherogenic role via its ability to 
drive the infiltration of pro-atherogenic myeloid cells to atherosclerotic aortas.30 While other 
STAT3-activating cytokines such as leptin have also been implicated in atherosclerosis, STAT3 
activation via the leptin receptor (LEPR) is unlikely to contribute to atherosclerosis since plaque 
formation (including the presence of aortic macrophages) was unaltered in ApoE-/- mice expressing 
a LEPR mutant unable to elicit STAT3 signalling.31 With respect to the role of gp130-activating 
cytokines during atherosclerosis, while IL-6 is the most widely investigated, its genetic ablation, 
transgenic over-expression or exogenous administration in atherosclerosis-prone mouse 
backgrounds have led to conflicting findings regarding its pro- or anti-atherogenic properties9,12,13,32. 
While the mechanistic basis for these diverse findings remain ill-defined, they reflect the complex 
spectrum of atherogenic-related cellular processes affected by IL-6 signalling, including lipid 
homeostasis, metabolism, vascular remodelling, and the recruitment and activation of inflammatory 
cells, the latter of which can manifest as either anti- or pro-inflammatory. 
Our data presented here raises the question as to which gp130 signalling pathway(s) 
independent of STAT3 influence atherosclerotic plaque formation. In light of the observed 
protection against atherosclerosis in gp130F/F mice, one would suggest the involvement of either 
suppressed pro-atherogenic or enhanced anti-atherogenic signalling from the mutant gp130 receptor. 
Such a pathway is unlikely to involve PI3K/Akt whose activation from gp130 is suppressed in 
gp130F/F mice, since the modulation of PI3K signalling in ApoE-/- mice on a PTEN-deficient 
background had no effect on high-fat diet-induced atherosclerosis33. In addition, genetic ablation of 
Akt1 or Akt3 isoforms in ApoE-/- mice has indicated an athero-protective role for Akt signalling in 
either the bone marrow or vascular compartments34,35. The notion that the absence of specific pro-
atherogenic gp130 signalling cascades in gp130F/F:ApoE-/- mice may be responsible for the reduced 
plaque formation is supported by the observation that ApoE-/- mice harbouring hepatic-specific 
conditional deletion of gp130 are also protected against atherosclerosis10. In this regard, while 
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studies with inhibitors against mammalian target of rapamycin (mTOR) in atherosclerotic ApoE-/- 
and Ldlr-/- mouse models have implicated a pro-atherogenic role for this pathway36, 37, we note that 
mTOR is over-activated in gp130F/F mice38.  
In summary, our current study provides further evidence in vivo for the importance of the 
gp130 cytokine receptor in modulating the development of atherosclerotic lesions. Furthermore, we 
identify that the gp130/STAT3 signalling axis plays a key role in directing the macrophage 
infiltration into aortic lesions and the acute phase response during atherosclerosis; however, these 
processes alone are not sufficient to influence disease pathogenesis. These data therefore implicate 
gp130/STAT3-independent signalling pathways in promoting the molecular pathogenesis of 
atherosclerotic disease, the future identification of which will further broaden our understanding of 
the complexities by which gp130-activating cytokines contribute to cardiovascular disease. 
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Figure Legends 
Figure 1 
Suppressed atherosclerosis in gp130F/F:ApoE-/- mice mice fed a high-fat diet. (A) Weight of 
ApoE-/- (n=9) and gp130F/F:ApoE-/- (n=9) mice at the beginning (week 0) and end (week 10) of 
being fed a high-fat diet. (B) Representative photomicrographs showing aortic root cross-sections 
stained with oil red O in ApoE-/- and gp130F/F:ApoE-/- mice after 10 weeks of being fed a high-fat 
diet. Arrows point to representative red-stained areas containing atherosclerotic plaques. Scale 
bars=200µm. (C, D) Quantitative analysis of oil red O-stained plaques as (C) a percentage within 
the whole aortic root and (D) total surface area in the aortic root. Data are from n=6 ApoE-/- and n=5 
gp130F/F:ApoE-/- mice, and are expressed as mean±SEM. ***P<0.001.  
 
Figure 2 
Reduced systemic levels of triclycerides in gp130F/F:ApoE-/- mice fed a high-fat diet. ApoE-/- and 
gp130F/F:ApoE-/- mice were fed a high-fat diet for 10 weeks, following which serum concentrations 
were measured for (A) triglycerides, (B) total cholesterol, (C) HDL cholesterol, and (D) LDL 
cholesterol. n=12 mice per genotype. Data are presented as the mean±SEM. **P<0.01.  
Figure 3 
Augmented aortic plaque macrophage infiltration and production of SAA in gp130F/F:ApoE-/- 
mice fed a high-fat diet. (A) Left panels; representative photomicrographs showing aortic root 
cross-sections stained with CD68 antibody in ApoE-/- and gp130F/F:ApoE-/- mice after 10 weeks of 
being fed a high-fat diet. Scale bars=100µm. Right panels; magnified area of the aortic root with 
CD68 staining. Scale bars=50µm. (B) Quantitative analysis of CD68+ cells within plaques 
expressed as a percentage of the total plaque surface area. Data are from n=4 ApoE-/- and 
gp130F/F:ApoE-/- mice, and are expressed as mean±SEM. **P<0.01. (C) ELISA of SAA protein 
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levels in the plasma of high fat diet-fed ApoE-/- and gp130F/F:ApoE-/- mice. Data are from n=4 ApoE-
/- and gp130F/F:ApoE-/- mice, and are expressed as mean±SEM. *P<0.05.  
Figure 4 
Activation of the gp130/STAT3 signalling axis does not influence atherosclerosis in gp130F/F 
mice. (A-D) Mice of the indicated genotypes were fed a high-fat diet for 10 weeks, following which 
serum concentrations were measured for (A) triglycerides, (B) total cholesterol, (C) HDL 
cholesterol, and (D) LDL cholesterol. n=5-6 mice per genotype. Data are presented as the 
mean±SEM. *P<0.05. (E) Representative photomicrographs showing aortic root cross-sections 
stained with oil red O in mice of the indicated genotypes after 10 weeks of being fed a high-fat diet. 
Arrows point to representative red-stained areas containing atherosclerotic plaques. Scale 
bars=200µm. (F, G) Quantitative analysis of oil red O-stained plaques as (F) a percentage within 
the whole aortic root and (G) total surface area in the aortic root. Data are from n=4 mice per 
genotype, and are expressed as mean±SEM. *P<0.05.   
Figure 5 
Altered gp130 signalling in gp130F/F bone marrow-derived immune cells does not influence 
atherosclerosis in ApoE-deficient mice. (A) Representative photomicrographs showing aortic root 
cross-sections stained with oil red O in recipient ApoE-/- mice reconstituted with bone marrow from 
gp130F/F:ApoE-/- mice (ApoEF/F:ApoE) or ApoE-/- mice (ApoEApoE) after 10 weeks of being fed a high-
fat diet. Arrows point to representative red-stained areas containing atherosclerotic plaques. Scale 
bars=200 µm. (B, C) Quantitative analysis of oil red O-stained plaques as (B) a percentage within 
the whole aortic root and (C) total surface area in the aortic root. Data are from n=4 ApoEApoE and 
n=5 ApoEF/F:ApoE mice. (D) Serum concentrations of triglycerides in naïve ApoE-/- (n=6) and 
gp130F/F:ApoE-/- (n=6) mice, as well as ApoEF/F:ApoE (n=5) and ApoEApoE (n=4) mice, after 10 
weeks fed on a high-fat diet. Data are presented as the mean±SEM. *P<0.05, **P<0.01. 
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Dear Editor, 
 
Please find enclosed our manuscript entitled “Modulation of atherosclerosis in ApoE-deficient 
mice by gp130 signalling independent of STAT3” by Gareth Jones and colleagues for your 
consideration for publication in Atherosclerosis.  
 
The gp130 cytokine receptor transduces signals from a large number of cytokines, known as the 
interleukin (IL)-6 cytokine family. Among these cytokines IL-6 is a potent modulator of many 
atherogenic-related processes including lipid homeostasis, metabolism, vascular remodelling, the 
acute phase response, and the recruitment and activation of inflammatory cells, the latter of 
which can manifest as either anti- or pro-inflammatory. However, the pathological role of 
specific IL-6/gp130 signalling cascades during atherosclerosis is ill-defined.  
 
IL-6 primarily activates the latent transcription factor STAT3 via gp130, and STAT3 itself has 
been implicated in atherosclerosis, albeit with controversial findings. This is largely due to 
different in vivo approaches to artificially modulate STAT3 activity, either indirectly by targeting 
the negative cytokine signalling regulator SOCS3 (which can also interfere with other pathways) 
or directly by modulating STAT3 expression levels. In addition, such approaches do not address 
which upstream cytokine receptor system is responsible for activation of STAT3 during disease. 
 
To address these issues and advance our fundamental understanding of the complex molecular 
and cellular basis by which the gp130 receptor influences atherosclerosis, we report here the use 
*Submission Letter  Suggested Reviewers
of a genetic approach with the gp130F/F knock-in mutant mouse characterized by hyper-activation 
of endogenous STAT3 to define whether endogenous gp130-dependent STAT3 activation 
modulates atherosclerosis.  
 
Specific novel findings of our current manuscript are as follows: 
1) aortic plaque development and plasma triglyceride levels were significantly reduced in 
gp130F/F:ApoE-/- mice fed a high-fat diet. 
2) the reduced atherosclerosis in gp130F/F:ApoE-/- mice surprisingly correlated with augmented 
CD68+ macrophage infiltrates in the smaller atherosclerotic plaques, and plasma serum amyloid 
A (as a read-out for the acute phase response) levels were elevated.  
3) genetic reduction of endogenous STAT3 activity in gp130F/F:Stat3-/+:ApoE-/- mice had no 
effect on atherosclerotic lesion development and plasma triglyceride levels, despite macrophage 
numbers in lesions and plasma SAA levels being significantly reduced back to wild-type levels.  
4) bone marrow chimeras revealed that the suppressed aortic plaque development and plasma 
triglyceride levels in gp130F/F:ApoE-/- mice were independent of gp130 signals in bone marrow 
(immune) cells. 
 
Thus, our current study provides new evidence in vivo for the importance of the gp130 cytokine 
receptor in modulating the development of atherosclerotic lesions. Furthermore, we also identify 
that while the endogenous gp130/STAT3 signalling axis plays a key role in directing the 
macrophage infiltration into aortic lesions and the acute phase response during atherosclerosis, 
these processes alone are not sufficient to influence disease pathogenesis. We believe these novel 
data therefore implicate gp130/STAT3-independent signalling pathways in promoting the 
molecular pathogenesis of atherosclerotic disease, the future identification of which will further 
broaden our understanding of the complexities by which gp130-activating cytokines contribute to 
atherosclerosis. In the burgeoning international climate of intense research into cardiovascular 
disease, as well as the role of cytokine signalling in general disease pathogenesis, we believe our 
novel mechanistic insights presented here are most timely and appropriate for dissemination 
among the broad readership of Atherosclerosis including molecular and cell biologists, as well as 
clinical researchers. 
 
Potential reviewers with particular expertise in the areas of atherosclerosis, the immune system 
and gp130 signalling include the following: 
Eicke Latz, expert in atherosclerosis and the immune system; Institute of Innate Immunity, 
University of Bonn, Germany; eicke.latz@uni-bonn.de 
Jurgen Scheller, expert in gp130 signalling; Heinrich-Heine-University, Germany; jscheller@uni-
duesseldorf.de 
Ban-Hock Toh, expert in atherosclerosis; Monash University, Australia; ban-
hock.toh@monash.edu 
Heike Hermanns, expert in gp130 signalling; University of Würzburg, Germany; 
heike.hermanns@virchow.uni-wuerzburg.de 
 
The authors declare that they have no conflict of interest. 
 
We also note that all authors are in agreement with submission of the manuscript to 
Atherosclerosis. 
 
We look forward to hearing from you at your earliest convenience. 
 Kind regards, 
 
Professor Brendan J. Jenkins, PhD (Med) 
Head, Cancer and Immune Signalling Laboratory  
Centre for Innate Immunity and Infectious Diseases,  
MIMR-PHI Institute of Medical Research,  
Monash University,  
27-31 Wright Street,  
Clayton, Victoria 3168, Australia. 
Tel +61 3 9902 4708; Fax +61 3 9594 7235; E-mail Brendan.Jenkins@monash.edu  
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